Printer Friendly
The Free Library
19,573,952 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

A.P. Pharma Provides APF112 Clinical Development Update; Phase II Data Expected by Mid-Year.


Business Editors/Health/Medical Writers

REDWOOD CITY Redwood City, city (1990 pop. 66,072), seat of San Mateo co., W Calif., on San Francisco Bay; inc. 1868. Manufactures include commmunications, electrical, electronic, and medical equipment. , Calif.--(BUSINESS WIRE)--Jan. 26, 2004

A.P. Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, today provided an update on the clinical development of its lead product candidate, APF APF,
n the abbreviation for acidulated phosphate fluoride.
112.

The multi-center Phase II study involving APF112 for the treatment of post-surgical pain, which commenced in the fourth quarter of 2003, is comprised of two parts. In November 2003, the Company indicated that they hoped to complete enrollment of this study in early 2004 and report results shortly thereafter. Recruitment in Part 1 of the study, an open-label safety assessment, was slower than anticipated due to initial caution on the part of clinical investigators that APF112 might interfere with the standard inguinal hernia inguinal hernia
n.
A hernia into the inguinal canal.


inguinal hernia Surgery The prolapse of a loop of intestine into a patent inguinal canal
 repair surgery. However, after clinical investigators completed several procedures using APF112, enrollment in the study increased.

According to according to
prep.
1. As stated or indicated by; on the authority of: according to historians.

2. In keeping with: according to instructions.

3.
 Dan J. Kopacz, M.D. of Virginia Mason Medical Center Virginia Mason Medical Center (VMMC), founded in 1920, is a private, non-profit organization located on Seattle, Washington's First Hill offering a system of integrated health services. Gary S. Kaplan, MD, serves as chairman and CEO, and J.  and a lead investigator in the APF112 Phase II trial, "Surgeons are often concerned that investigational pain drugs might somehow impede surgery or lead to unforeseen complications after surgery, as has happened in the past. Presuming pre·sum·ing  
adj.
Having or showing excessive and arrogant self-confidence; presumptuous.



pre·suming·ly adv.
 my experience is typical, following use with APF112 it was clear that the product in no way interferes with surgical technique and did not result in post-surgical complications. Now that clinical investigators have a comfort level with this product, patient recruitment in the clinical trial has ramped up."

Part II of the trial, a 90-patient blinded study comparing two doses of APF112 with current standard treatments for managing post-operative pain, is expected to begin in the near future. A.P. Pharma also announced that it has increased the number of clinical sites able to participate in the study to 12. The Company expects to have preliminary APF112 Phase II clinical data by mid-year. The clinical endpoints for the study include the evaluation of safety and tolerability, a visual analog score of pain intensity, the standard means of measuring pain, and reduction in use of opioid-type pain medication.

APF112 combines A.P. Pharma's proprietary Biochronomer(TM) bioerodible drug delivery system with mepivacaine, an off-patent analgesic analgesic (ăn'əljē`zĭk), any of a diverse group of drugs used to relieve pain. Analgesic drugs include the nonsteroidal anti-inflammatory drugs (NSAIDs) such as the salicylates, narcotic drugs such as morphine, and synthetic drugs . APF112 is designed to provide 24 to 36 hours of pain relief while minimizing the use of opioid-type drugs, which are used extensively in post-operative pain management. Opioids are associated with a number of side effects Side effects

Effects of a proposed project on other parts of the firm.
, such as nausea, sedation Sedation Definition

Sedation is the act of calming by administration of a sedative. A sedative is a medication that commonly induces the nervous system to calm.
Purpose

The process of sedation has two primary intentions.
, dizziness, constipation, vomiting, urinary retention Urinary retention
The result of progressive obstruction of the urethra by an enlarging prostate, causing urine to remain in the bladder even after urination.
, and in some situations life-threatening respiratory depression.

About A.P. Pharma

A.P. Pharma is a specialty pharmaceutical company focused on the development of ethical (prescription) pharmaceuticals utilizing its proprietary polymer-based drug delivery systems. The Company's primary focus is the development and commercialization of its bioerodible injectable and implantable systems under the trade name Biochronomer. Initial target areas of application for the Company's drug delivery technology include pain management, anti-nausea, inflammation, oncology and ophthalmology applications. The Company's product development programs are funded by royalties from topical products currently marketed by pharmaceutical partners, by proceeds from the divestitures of its cosmeceutical cos·me·ceu·ti·cal
n.
A cosmetic that has or is purported to have medicinal properties.
 and analytical standards product lines and by fees it receives from collaborative partners. For further information, visit the Company's web site at www.appharma.com.

Forward-looking Statements

Except for historical information, this news release contains certain forward-looking statements that involve risks and uncertainties including, among others, uncertainty associated with timely development, approval, launch and acceptance of new products, establishment of new corporate alliances and progress in research and development programs. Other risks and uncertainties associated with the Company's business and prospects are identified in the Company's filings with the Securities and Exchange Commission. The Company does not undertake to revise these forward-looking statements to reflect events or circumstances occurring in the future.
COPYRIGHT 2004 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jan 26, 2004
Words:605
Previous Article:Leading Exercise Physiology Scientist from University of Wisconsin-La Crosse Finds Next-Generation SLENDERTONE FLEX Abdominal Belt Highly Effective...
Next Article:ADVISORY/Connexn Technologies' Executive to Share New Strategies for Successful Cost and Revenue Assurance at IIR Conference.



Related Articles
SCHWARZ PHARMA ACQUIRES RIGHTS TO DRUG FOR EPILEPSY.
A.P. Pharma Establishes Timetable to Re-Initiate Clinical Program for APF112; Company provides regulatory update on progress towards Phase II...
A.P. Pharma Reports Fourth Quarter and Year-End 2002 Results.
A.P. Pharma Reports First Quarter Results; Royalty Income Increases by 14% Over Q1 2002.
A.P. Pharma Reports Second Quarter Results; APF112 Phase II Clinical Package Submitted for FDA Review; Royalty Income Increases 11% Over 2Q 2002.
A.P. Pharma Ready to Initiate Phase II Studies With APF112; Company Plans to Initiate Phase II Clinical Trials in September.
A.P. Pharma Reports 2003 Fourth Quarter and Full Year Results; Reports Results of Open-Label APF112 Phase 2 study.
A.P. Pharma Initiates Phase I Clinical Trial with APF530, a Potential Treatment for Chemotherapy-Induced Nausea and Vomiting.
A.P. Pharma Reports Third Quarter Financial Results; APF530 Phase 1 Study Successfully Completed.
Astellas Discontinues Development of Alzheimer's Disease Compound FK962.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles